Follows people with beta-thalassemia treated with betibeglogene autotemcel over time
Collects long-term safety and effectiveness data on beta-thalassemia patients treated with betibeglogene autotemcel.
Key facts
- Who runs it
- Genetix Biotherapeutics Inc.
- Where
- Houston, Minneapolis, New Hyde Park, Oakland, Palo Alto, and Philadelphia, United StatesSee the 6 sites
- Trial code
- Registry title
- A Study of Participants with Β-Thalassemia Treated with Betibeglogene Autotemcel
- Status
- Recruiting
- People taking part
- 150 people, planned
- Started
- 23 Jan 2024
- Expected to end
- Dec 2043
- Type of study
- Observational
- Record updated
- 11 February 2025
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for people with β-thalassemia who were treated with betibeglogene autotemcel (beti-cel) at a US center in the registry. It collects long-term safety and effectiveness data.
- Sex
- All sexes can join.
- Earlier treatment
- Must have been treated with beti-cel in the post marketing setting at a US center that takes part in the Registry.
Main reasons for not taking part
- The record lists no exclusion criteria.
The registry criteria, word for word
Show all 5 criteriaShow less
Who can take part
- Participant must be treated with beti-cel in the post marketing setting at a center in the US that participates in the Registry
- Participant must sign an informed consent and/or assent prior to enrollment as required under applicable laws and regulations
- Participant must have signed an informed consent and/or assent permitting data to be shared with Center for International Blood and Marrow Transplant Research (CIBMTR)
- Participant must be followed by a hematologist based in the US
Who cannot take part
- There are no exclusion criteria for Registry participation
Where in United States
- Texas Children's HospitalHouston, United StatesContact: bluebird bioTaking people
- University of MinnesotaMinneapolis, United StatesContact: bluebird bioTaking people
- Cohen Children's Medical CenterNew Hyde Park, United StatesContact: bluebird bioTaking people
- UCSF Benioff Children's HospitalsOakland, United StatesContact: bluebird bioTaking people
- Stanford UniversityPalo Alto, United StatesContact: bluebird bioTaking people
- Children's Hospital of PhiladelphiaPhiladelphia, United StatesContact: bluebird bioTaking people
About the trial
What the trial wants to find out
The main aim of this study is to collect real-world longitudinal data on participants with β-thalassemia treated with betibeglogene autotemcel (beti-cel) in the post marketing setting. To assess the long-term safety, including the risk of newly diagnosed malignancies, after treatment with beti-cel and evaluate the long-term effectiveness of treatment with beti-cel.
The group in the trial
- All Participants
Participants with β-thalassemia treated with beti-cel in the post-marketing setting will be followed in this registry study for up to 15 years after infusion with beti-cel to collect real-world longitudinal data.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorSaves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Safety and Effectiveness Registry Study of Patients with Β-Thalassemia Treated with Betibeglogene Autotemcel (the Glostar Registry)
- Plain-language title
- Follows people with beta-thalassemia treated with betibeglogene autotemcel over timeGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Record updated
- 11 February 2025